CoChat

Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Open access
Krepler, Clemens, Xiao, Min, Sproesser, Katrin, Brafford, Patricia A., Shannan, Batool, Beqiri, Marilda, Liu, Qin, Xu, Wei, Garman, Bradley, Nathanson, Katherine L., Xu, Xiaowei, Karakousis, Giorgos C., Mills, Gordon B., Lu, Yiling, Ahmed, Tamer A., Poulikakos, Poulikos I., Caponigro, Giordano, Boehm, Markus, Peters, Malte, Schuchter, Lynn M., Weeraratna, Ashani T., Herlyn, Meenhard · 2016 · Clinical Cancer Research
Cited by 140

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models. Experimental Design: We established 12 PDXs from BRAF inhibitor–progressed melanoma patients. Following expansion, PDXs were analyzed using targeted sequencing and reverse-phase protein arrays. By using multi-arm preclinical trial designs, we identified efficacious precision medicine approaches. Results: We identified alterations previously described as drivers of resistance: NRAS mutations in 3 PDXs, MAP2K1 (MEK1) mutations in 2, BRAF amplification in 4, and aberrant PTEN in 7. At the protein level, re-activation of phospho-MAPK predominated, with parallel activation of PI3K in a subset. Second-line efficacy of the pan-PI3K inhibitor BKM120 with either BRAF (encorafenib)/MEK (binimetinib) inhibitor combination or the ERK inhibitor VX-11e was confirmed in vivo. Amplification of MET was observed in 3 PDX models, a higher frequency than expected and a possible novel mechanism of resistance. Importantly, MET amplification alone did not predict sensitivity to the MET inhibitor capmatinib. In contrast, capmatinib as single agent resulted in significant but transient tumor regression in a PDX with resistance to BRAF/MEK combination therapy and high pMET. The triple combination capmatinib/encorafenib/binimetinib resulted in complete and sustained tumor regression in all animals. Conclusions: Genomic and proteomic data integration identifies dual-core pathway inhibition as well as MET as combinatorial targets. These studies provide evidence for biomarker development to appropriately select personalized therapies of patients and avoid treatment failures. Clin Cancer Res; 22(7); 1592–602. ©2015 AACR. See related commentary by Hartsough and Aplin, p. 1550

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-1762

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 140

Metadata

Authors
Krepler, C., Xiao, M., Sproesser, K., Brafford, P. A., Shannan, B., Beqiri, M., Liu, Q., Xu, W., Garman, B., Nathanson, K. L., Xu, X., Karakousis, G. C., Mills, G. B., Lu, Y., Ahmed, T. A., Poulikakos, P. I., Caponigro, G., Boehm, M., Peters, M., Schuchter, L. M., Weeraratna, A. T., & Herlyn, M.
Venue
Clinical Cancer Research
Published
2016-03-31
Volume
22
Issue
7
Pages
1592-1602
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2207662183
Cited by
140
References
9
FWCI
7.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1762
The paper
Krepler, C., Xiao, M., Sproesser, K., Brafford, P. A., Shannan, B., Beqiri, M., Liu, Q., Xu, W., Garman, B., Nathanson, K. L., Xu, X., Karakousis, G. C., Mills, G. B., Lu, Y., Ahmed, T. A., Poulikakos, P. I., Caponigro, G., Boehm, M., Peters, M., . . . Herlyn, M. (2016). Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1762

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.